Exploit the full potential of liquid biopsy technology
Cancer researchers have an exciting new tool at their disposal: circulating cell-free DNA (ccfDNA) collected in minimally invasive liquid biopsies. With the potential to provide real-time mutational information about primary and metastatic tumors, cfDNA has significant potential for the detection and monitoring of biomarkers for cancer and other diseases. ...
Read more
Cancer researchers have an exciting new tool at their disposal: circulating cell-free DNA (ccfDNA) collected in minimally invasive liquid biopsies. With the potential to provide real-time mutational information about primary and metastatic tumors, cfDNA has significant potential for the detection and monitoring of biomarkers for cancer and other diseases. Compared with static sampling of DNA from an archival/FFPE tumor specimen, ccfDNA can provide real-time mutational information of primary and metastatic tumors. And this can greatly improve treatment decisions and monitoring.
Because ccfDNA is often found in low concentrations with rare mutations or in fragmented condition, workflows must be sensitive and reliable. QIAGEN provides everything researchers need to gain deep insight into ccfDNA: a complete and streamlined workflow covering collection and stabilization, isolation, analysis and data interpretation. Check out our solutions below!
Hide details